AKT1 and breast cancer: Currently, AKT inhibitor and STING agonists (STINGa) have been proved for clinical application or clinical trials.[19] We proved that inactivated cGAS–STING signaling and hyperactivated AKT1 formed a positive feedback loop to mediate endocrine resistance in endocrine‐resistant breast cancer.